Together, they may affect the antigenic determinant of the C-term

Together, they may affect the antigenic determinant of the C-terminal part of the ZnT8. Comparing Rapamycin ic50 the results on the human patient sera between the short

ZnT8 peptide and the long ZnT8 protein suggests that it should be possible to identify the minimum requirement for the conformational epitope by deletion mutants followed by, for example, alanine replacement scanning. Whether the difference of the binding affinity between the R and W protein in the ZnT8WAb-specific patient, P5-W, may be a result from lack of epitope spreading due to early diabetes-onset (2.3 years) needs to be clarified. Age-specific antibody affinity was previously reported for IAAb in children with high T1D risk [28]. In addition,

it is important to take the HLA-DQ genotype into account as ZnT8WAb and ZnT8QAb were more often found in newly diagnosed patients with HLA-DQ8, while all three ZnT8Ab variants were more often associated with DQ6.4 [29]. Future studies of children at risk of T1D such as the TEDDY [30], DiPiS [31], DAISY [32] and BABY-DIAB MK-2206 solubility dmso [33] should therefore take into account not only the HLA genotype but also the SLC30A8 gene polymorphism and the ZnT8Ab variant specificity and affinity in the attempts to predict the clinical onset of autoimmune diabetes. Six patients were selected for the present investigation. The patients are unique as they showed monospecificity to either ZnT8RAb or ZnT8WAb. The analysis required significant volumes of serum which was not always available from patients tested at the time of clinical diagnosis. In our previous study, we have found that 15.6% of the patients had monospecific

ZnT8RAb and 10.3% monospecific ZnT8WAb [16]. A strength to the present study is the novel approach to combine the ZnT8tripleAb screening [16] to first identify subjects with any ZnT8Ab with the monospecific ZnT8 autoantibody assays to be followed by competition analysis with cold protein. In future studies, known amounts of recombinant proteins will be needed to reliably CYTH4 determine affinity at the 325-associated epitope. Our study should prove useful for further studies of the contribution of epitope-specific ZnT8Ab in the pathogenesis of T1D. We believe that the epitope analysis should be combined with affinity determinations to better define ZnT8Ab-positive subjects at risk of diabetes [30, 31]. In conclusion, the 325-epitope is likely to be dependent on the amino acid residues extending from the short (318–331) peptide. This suggests that the ZnT8Ab are directed against a broader epitope represented than a single amino acid. Further analyses of epitope-specific sera both before and at the clinical diagnosis of diabetes are warranted to dissect the possible importance of ZnT8 epitope-specific autoantibodies and loss of beta cells. We thank Anita Nilsson and Ingrid Wigheden for expert advice.

This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>